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Abstract
It has been shown that partial amino acid sequence homology between a gliadin and an early region protein (EIB-58 kDa) of adenovirus 12 results in immunological cross reaction. This led to the proposal that prior infection by adenovirus 12 could be associated with the development of coeliac disease. To examine this hypothesis, evidence was sought of persistent adenovirus 12 infection in the small intestinal mucosa ofpatients with coeliac disease. DNA isolated from biopsy samples from 24 control and 18 coeliac disease patients was analysed by the polymerase chain reaction for adenovirus 12 DNA encoding the E1B-58 kDa protein. Four of 18 coeliac disease and two of 24 control patients were positive. There is thus a low prevalence of this infection on both groups of patients but certainly no significantly increased incidence in coeliac disease. These results suggest that persistent Agarose gel electrophoretic analysis ofpolymerase chain reaction (PCR) products. PCR products using adenovirus (Ad) 12 A different approach to this hypothesis would be to seek evidence of persistent adenovirus 12 infection in patients with coeliac disease. Persistent infection would require continuing viral replication, and since the early region proteins (EIA and E1B) are involved in the initiation of replication, one would expect to find evidence of the early protein genes in a persistent infection. Hence we have used the polymerase chain reaction to seek evidence of persisting viral infection in small intestinal mucosa using specific oligonucleotide primers for the EIB-58 kDa gene. This is particularly appropriate since it is the E1B-58 kDa protein that is involved in the original hypothesis.
Patients and methods Upper small intestinal mucosal biopsy specimens were taken from 24 control and 18 coeliac disease patients. Twelve of the control patients were men; the mean age was 41 years (range 9-70). Intestinal biopsy was performed for the routine investigation of diarrhoea (9) , dyspepsia (7), anaemia (5), short stature (1), weight loss (1), and lymphangiectasia (1) . All biopsy specimens had normal histological appearances, except for variable dilated lymphatics in the patient with lymphangiectasia.
Ten of the 18 coeliac disease patients were men; the mean age was 49 years (range 23-73). Eleven patients have been treated with a gluten free diet for at least one year (mean [5] [6] years, range 1-20). All had shown a good clinical and histological response to the gluten free diet. Seven patients were newly diagnosed and had the typical histological features of untreated coeliac disease. They have yet to undergo further biopsy to assess the effect of a gluten free diet. This study was approved by the local ethical committee.
The biopsy specimens were immediately stored frozen at -70°C until processing was performed (maximum storage time two months). They were homogenised in acid washed glass homogenisers with 0 1 ml 10 mmol/A Tris-HCl (pH 8.0), 1 mmol/l EDTA. Further homogenisation was performed after the addition of 1 0 ml lysis buffer (0.5% Sarkosyl, 0.5 mol/l EDTA), proteinase K was added to the pooled mixture to a final concentration of 150 ,ug/ml, and it was incubated for 18 hours at 37°C. Samples were then extracted with phenol and dialysed overnight at 4°C in TEN buffer (50 mmol/l Tris-HCl pH 8-0, 10 mmol/l NaCl, 10 mmol/l EDTA). Polymerase chain reaction analysis was performed (in 50 lp reactions) using 100 ng genomic DNA, 1 p,mol/l oligonucleotide primers, 10 mmol/l Tris-HC1 (pH 8.3), 50 mmol/l KC1, 1 5 mmol/l MgCl2, 0-1% Triton X-100, 0-01% gelatin, 0-2 mmolA each dATP, dCTP, dGTP, and dTTP (Pharmacia) and 2.5 units Taq polymerase (Promega). Reactions were overlaid with 20 p1 light mineral oil and denatured for seven minutes at 95°C. They were then subjected to 30 cycles of the following programme in a thermocycler (Perkin Elmer Cetus): 60°C, one minute; 72°C, one and a half minutes; 95°C, one minute. An aliquot (15 p1l) of the reaction products was analysed by electrophoresis on a 2% agarose gel containing 10 ,ig/ml ethidium bromide.
The following oligonucleotides were used (with their positions given on the adenovirus 12 DNA sequence):
Adl2 E1B# 1 5'> CTGTTCATATTGTGAGCCAC>3' (NT 2912 (NT -2931 Adl2 E1B#2 5'> AAGGTGGTCACTTCTCAGCT>3' (NT 3240-3221) Adl2 E1B#3 5'> CTAGATGACTGCTACCACAC>3' Primers #1 and #2 generated a 329 bp polymerase chain reaction product and #1 and #3 Figure 1 shows that primers #1 and #2 (tracks a) yielded a 329 bp product using DNA of three coeliac disease and two control patients, while primers #1 and #3 gave the expected 257 bp species (tracks b) from the same patients. The 329 and 257 bp fragments generated from patient material exactly comigrated with the polymerase chain reaction products from the adenovirus 12 transformed cell DNA, strongly suggesting that these polymerase chain reaction products had been amplified from adenovirus 12 DNA sequences. Control rat liver DNA did not generate either polymerase chain reaction product. Restriction endonuclease analysis of the patient's polymerase chain reaction products using the enzymes Taq I or RsaI gave fragments with sizes expected from the published adenovirus 12 E1B DNA sequence8 (results not shown). To prove conclusively that the 329 bp polymerase chain reaction product was indeed derived from adenovirus 12 DNA, the double stranded product was subjected to DNA sequencing by the dideoxy method. The partial DNA sequence of the polymerase chain reaction product of a coeliac disease patient was identical to that of the 329 bp product from the adenovirus 12 transformed rat cell (Fig 2) . The partial DNA sequences of the polymerase chain reaction products from coeliac disease and control patients and the adenovirus 12 transformed rat cell were identical to the published E1B sequence of adenovirus 12 viral DNA (Fig 3) .8 This conclusively establishes the identity of the polymerase chain reaction products from the coeliac disease and control patient samples as adenovirus 12 E1B DNA.
Prevalence ofadenovirus (Ad) 12 Although adenovirus 12 E1B DNA sequences could be detected in the mucosa of some coeliac disease patients, most did not contain amplifiable E1B DNA sequences (Table) . An approximately similar proportion of control patients also contained adenovirus 12 E1B DNA. There is no statistically significant difference between these two groups of patients. For example, two of the five coeliac disease patients tested in Figure 1 did not show amplifiable E1B DNA sequences with either combination of primers. Reamplification of polymerase chain reaction products has been reported to increase the sensitivity of the assay,9 but this did not generate adenovirus 12 E1B polymerase chain reaction products in samples that were negative in the first polymerase chain reaction (not shown). To confirm that all DNA samples tested were amplifiable, the polymerase chain reaction was performed using primers to the human p53 antioncogene. All DNA samples were amplified using these primers (not shown). Thus, although a proportion of coeliac disease patients contain adenovirus 12 E1B DNA in the intestinal mucosa, this does not correlate with the incidence of the disease and may reflect the general incidence of adenovirus 12 
